PROFILE: Paula Salmikangas, chair of the Committee for Advanced Therapies at the European Medicines Agency, on handicrafts, picking berries and the very first stem cell therapy
This article was originally published in SRA
Executive Summary
The European Medicines Agency's Committee for Advanced Therapy Medicinal Products (CAT) evaluates the quality, safety and efficacy of ATMPs. Senior Finnish regulator Paula Salmikangas* has chaired the committee since February 2014. In this profile, Dr Salmikangas talks to Francesca Bruce about the pitfalls of rushing a product from bench to patient and the value to companies of talking to regulators – and of her passion for berry-picking and the musical Phantom of the Opera.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.